To the Editor: Although safe use of oral retinoids with dermabrasion and resurfacing laser procedures have been reported in patients on isotretinoin, waiting 6-12 months after isotretinoin cessation is typically recommended before undergoing elective surgery. 1, 2 This recommendation arose from theoretical concern and from 9 prior cases (6 dermabrasions, 3 laser procedures) of delayed wound healing or keloid formation after cosmetic procedures in patients on isotretinoin. 2, 3 We aimed to evaluate the prevalence of scarring and postoperative complications in patients exposed and not exposed to isotretinoin in the perioperative period.
One thousand six patients with isotretinoin and its brand names mentioned in their medical records from 1995-2011 were identified from the Mayo Clinic Data Discovery and Query Builder clinical database; medical records were searched for procedures in which a skin incision was made (Fig 1) . After 282 patients were excluded because of unclear isotretinoin exposure, the patients were divided into 3 groups on the basis of isotretinoin exposure: exposed to isotretinoin within 2 years before surgery, exposed to isotretinoin [2 years before surgery, acne severe enough for mention of but never exposed to isotretinoin who underwent surgery within 2 years before surgery. Each group was followed for at least 2 years after surgery to look for surgically related adverse events (AE) defined as significant or abnormal scarring, wound infection, poor healing, excessive bleeding, and wound dehiscence.
Within 2 years of follow-up after surgery, 2 of 76 (2.6%) patients who had incisional surgery with exposure to perioperative isotretinoin and 2 of The first day of treatment with isotretinoin was set as day 0 for the exposed group. The first mention of isotretinoin was day 0 for the unexposed. Medical records were searched for incisional surgeries. Surgeries up until 2 years from the day 0 for both groups were recorded and beyond the 2 years in the exposed. Surgeries undergone by the patients include dermabrasion, odontectomy, breast surgery (reduction mammoplasty, capsulotomy, augmentation), orthopedic surgery, thyroidectomy, parathyroidectomy, excision with layered closure, excisional biopsy, abdominal liposuction, incision and drainage, Mohs micrographic surgery, dermal grafting, hernia repair, salicylic acid peel, adenoidectomy, caesarian section, laser photocoagulation, diode laser hair removal, septoplasty, gingival grafting, laparoscopic procedures (cholecystectomy, nephrectomy, Roux-en-Y gastric bypass), open procedures (hysterectomy, cholecystectomy), and myringotomy. 82 (2.4%) patients who had surgery without exposure to isotretinoin experienced AE related to surgery. Of the 2 exposed patients with an AE, 1 was taking isotretinoin at the time of surgery and continued postoperatively until course completion and 1 had completed the course 2 months prior (Table I) . Oral retinoids have been associated with suppression of collagenase, potentially causing excessive collagen accumulation and keloid formation, and possible atrophy of the pilosebaceous unit, where re-epithelialization for wound healing originates. [1] [2] [3] [4] [5] A review of the literature showed that the AEs associated with surgical procedures performed on persons with isotretinoin exposure included nasal tip deformities (2 patients), slow wound healing (1 of 3 patients undergoing otolaryngologic surgery), slow healing (1 patient undergoing pilonidal cyst excision), and dry socket (3 of 25 patients with wisdom teeth extractions) ( Table I) . 5 The largest published study of 183 patients who underwent 504 surgical interventions while on isotretinoin reported 2 AE (0.4%) of keloid formation: 1 after radiofrequency ablation and the other after glycolic acid peel. 4 These complications could have been attributed to the aforementioned procedures; thus a causative effect of isotretinoin exposure was not clearly demonstrated.
Our study evaluated surgical outcomes in an otherwise healthy and similar population of patients exposed and unexposed to isotretinoin who had a large number and variety of incisional procedures. The large sample of patients with acne severe enough to be considered for isotretinoin therapy allowed us to effectively control for acne severity, a factor which could also contribute to scar formation or alteration in wound healing.
In summary, from medical record review, wound healing did not appear to be affected, and abnormal scarring did not appear to be evident in patients undergoing isotretinoin therapy as compared with those not exposed to the medication in the perioperative period. Because this study is limited by an overall low level of AE and its retrospective nature, the findings challenge the current practice of waiting 6-12 months to have elective surgery after isotretinoin exposure. Taking into consideration the small pool of case-based literature from which the recommendation to discontinue isotretinoin developed, a re-evaluation of this practice should be considered. Methotrexate treatment in patients with a history of cutaneous melanoma and the risk of a consecutive primary melanoma: A national retrospective registry-based cohort study
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